Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Yaz ad gets FDA-OK make-over

Executive Summary

Bayer is airing a corrective television ad campaign for its oral contraceptive Yaz (drospirenone/ethinyl estradiol), in response to an agency warning letter it received last fall (1"The Pink Sheet," Oct. 13, 2008, p. 21). The campaign will more clearly say Yaz is indicated to treat symptoms for premenstrual dysphoric disorder, not premenstrual syndrome, and moderate, not mild, acne. The ad is markedly different from the 2008 campaign and features one woman talking about the product and indications (with no balloons), Bayer said. It will run through August

You may also be interested in...



Advertising Citations Reach Record High: Another Way To Regulate Pharma?

FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month

EU Joint Regulatory Assessment Project Bears Fruit In COVID-19

The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.

The Case For Covaxin: Ocugen CEO Shankar Musunuri

A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries. 

Topics

UsernamePublicRestriction

Register

PS050675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel